Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial

Emma M Harding-Esch, Tansy Edwards, Harran Mkocha, Beatriz Munoz, Martin J Holland, Sarah E Burr, Ansumana Sillah, Charlotte A Gaydos, Dianne Stare, David C W Mabey, Robin L Bailey, Sheila K West, PRET Partnership, Emma M Harding-Esch, Tansy Edwards, Harran Mkocha, Beatriz Munoz, Martin J Holland, Sarah E Burr, Ansumana Sillah, Charlotte A Gaydos, Dianne Stare, David C W Mabey, Robin L Bailey, Sheila K West, PRET Partnership

Abstract

Background: Blinding trachoma, caused by ocular infection with Chlamydia trachomatis, is targeted for global elimination by 2020. Knowledge of risk factors can help target control interventions.

Methodology/principal findings: As part of a cluster randomised controlled trial, we assessed the baseline prevalence of, and risk factors for, active trachoma and ocular C. trachomatis infection in randomly selected children aged 0-5 years from 48 Gambian and 36 Tanzanian communities. Both children's eyes were examined according to the World Health Organization (WHO) simplified grading system, and an ocular swab was taken from each child's right eye and processed by Amplicor polymerase chain reaction to test for the presence of C. trachomatis DNA. Prevalence of active trachoma was 6.7% (335/5033) in The Gambia and 32.3% (1008/3122) in Tanzania. The countries' corresponding Amplicor positive prevalences were 0.8% and 21.9%. After adjustment, risk factors for follicular trachoma (TF) in both countries were ocular or nasal discharge, a low level of household head education, and being aged ≥ 1 year. Additional risk factors in Tanzania were flies on the child's face, being Amplicor positive, and crowding (the number of children per household). The risk factors for being Amplicor positive in Tanzania were similar to those for TF, with the exclusion of flies and crowding. In The Gambia, only ocular discharge was associated with being Amplicor positive.

Conclusions/significance: These results indicate that although the prevalence of active trachoma and Amplicor positives were very different between the two countries, the risk factors for active trachoma were similar but those for being Amplicor positive were different. The lack of an association between being Amplicor positive and TF in The Gambia highlights the poor correlation between the presence of trachoma clinical signs and evidence of C. trachomatis infection in this setting. Only ocular discharge was associated with evidence of C. trachomatis DNA in The Gambia, suggesting that at this low endemicity, this may be the most important risk factor.

Trial registration: ClinicalTrials.gov NCT00792922.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Location of study districts in…
Figure 1. Location of study districts in The Gambia.
Figure 2. Location of Kongwa district in…
Figure 2. Location of Kongwa district in Tanzania.

References

    1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
    1. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol. 2009;93:563–568.
    1. WHO. Report of the eighth meeting of the WHO Alliance for the Global Elimination of Blinding Trachoma, Geneva: Switzerland. 2004. .
    1. Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A, et al. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis. 2003;3:372–381.
    1. Harding-Esch EM, Edwards T, Sillah A, Sarr I, Roberts CH, et al. Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020? PLoS Negl Trop Dis. 2009;3:e573.
    1. WHO. 2008. Trachoma Data Form World Health Organization Alliance for the Global Elimination of Blinding Trachoma, Twelfth Meeting Geneva, Switzerland: 28–30 April 2008.
    1. Baral K, Osaki S, Shreshta B, Panta CR, Boulter A, et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ. 1999;77:461–466.
    1. Holm SO, Jha HC, Bhatta RC, Chaudhary JS, Thapa BB, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ. 2001;79:194–200.
    1. Burton MJ, Holland MJ, Faal N, Aryee EA, Alexander ND, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci. 2003;44:4215–4222.
    1. Miller K, Schmidt G, Melese M, Alemayehu W, Yi E, et al. How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol. 2004;11:255–262.
    1. Solomon AW, Harding-Esch E, Alexander ND, Aguirre A, Holland MJ, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med. 2008;358:1870–1871.
    1. Abdou A, Nassirou B, Kadri B, Moussa F, Munoz BE, et al. Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger. Br J Ophthalmol. 2007;91:13–17.
    1. West SK, Rapoza P, Munoz B, Katala S, Taylor HR. Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area. J Infect Dis. 1991;163:752–756.
    1. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65:477–483.
    1. Solomon AW, Holland MJ, Burton MJ, West SK, Alexander ND, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362:198–204.
    1. Dalesio N, Marsiglia V, Quinn A, Quinn TC, Gaydos CA. Performance of the MagNA pure LC robot for extraction of Chlamydia trachomatis and Neisseria gonorrhoeae DNA from urine and swab specimens. J Clin Microbiol. 2004;42:3300–3302.
    1. Faal H, Minassian DC, Dolin PJ, Mohamed AA, Ajewole J, et al. Evaluation of a national eye care programme: re-survey after 10 years. Br J Ophthalmol. 2000;84:948–951.
    1. Dolin PJ, Faal H, Johnson GJ, Minassian D, Sowa S, et al. Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet. 1997;349:1511–1512.
    1. ITI. 2009. Tanzania .
    1. Harding-Esch EM, Edwards T, Sillah A, Sarr-Sissoho I, Aryee EA, et al. Risk factors for active trachoma in The Gambia. Trans R Soc Trop Med Hyg. 2008;102:1255–1262.
    1. Schemann JF, Sacko D, Malvy D, Momo G, Traore L, et al. Risk factors for trachoma in Mali. Int J Epidemiol. 2002;31:194–201.
    1. Montgomery MA, Desai MM, Elimelech M. Assessment of latrine use and quality and association with risk of trachoma in rural Tanzania. Trans R Soc Trop Med Hyg 2009
    1. Fouad D, Mousa A, Courtright P. Sociodemographic characteristics associated with blindness in a Nile Delta governorate of Egypt. Br J Ophthalmol. 2004;88:614–618.
    1. Zack R, Mkocha H, Zack E, Munoz B, West SK. Issues in defining and measuring facial cleanliness for national trachoma control programs. Trans R Soc Trop Med Hyg. 2008;102:426–431.
    1. Edwards T, Cumberland P, Hailu G, Todd J. Impact of health education on active trachoma in hyperendemic rural communities in Ethiopia. Ophthalmology. 2006;113:548–555.
    1. West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 1995;345:155–158.
    1. Hsieh YH, Bobo LD, Quinn TO, West SK. Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol. 2000;152:204–211.
    1. West SK, Munoz B, Lynch M, Kayongoya A, Mmbaga BB, et al. Risk factors for constant, severe trachoma among preschool children in Kongwa, Tanzania. Am J Epidemiol. 1996;143:73–78.
    1. West SK, Congdon N, Katala S, Mele L. Facial cleanliness and risk of trachoma in families. Arch Ophthalmol. 1991;109:855–857.
    1. Baggaley RF, Solomon AW, Kuper H, Polack S, Massae PA, et al. Distance to water source and altitude in relation to active trachoma in Rombo district, Tanzania. Trop Med Int Health. 2006;11:220–227.
    1. Brechner RJ, West S, Lynch M. Trachoma and flies. Individual vs environmental risk factors. Arch Ophthalmol. 1992;110:687–689.
    1. Emerson PM, Bailey RL, Mahdi OS, Walraven GE, Lindsay SW. Transmission ecology of the fly Musca sorbens, a putative vector of trachoma. Trans R Soc Trop Med Hyg. 2000;94:28–32.
    1. Emerson PM, Bailey RL, Walraven GE, Lindsay SW. Human and other faeces as breeding media of the trachoma vector Musca sorbens. Med Vet Entomol. 2001;15:314–320.
    1. Emerson PM, Simms VM, Makalo P, Bailey RL. Household pit latrines as a potential source of the fly Musca sorbens–a one year longitudinal study from The Gambia. Trop Med Int Health. 2005;10:706–709.
    1. Emerson PM, Lindsay SW, Alexander N, Bah M, Dibba SM, et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet. 2004;363:1093–1098.
    1. Simms VM, Makalo P, Bailey RL, Emerson PM. Sustainability and acceptability of latrine provision in The Gambia. Trans R Soc Trop Med Hyg. 2005;99:631–637.
    1. Taylor HR, West SK, Mmbaga BB, Katala SJ, Turner V, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol. 1989;107:1821–1825.
    1. Polack SR, Solomon AW, Alexander ND, Massae PA, Safari S, et al. The household distribution of trachoma in a Tanzanian village: an application of GIS to the study of trachoma. Trans R Soc Trop Med Hyg. 2005;99:218–225.
    1. West S, Lynch M, Turner V, Munoz B, Rapoza P, et al. Water availability and trachoma. Bull World Health Organ. 1989;67:71–75.
    1. Bailey R, Downes B, Downes R, Mabey D. Trachoma and water use; a case control study in a Gambian village. Trans R Soc Trop Med Hyg. 1991;85:824–828.
    1. Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int J Epidemiol. 1989;18:944–951.
    1. Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis. 2005;5:313–320.
    1. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630–635.
    1. Bobo L, Munoz B, Viscidi R, Quinn T, Mkocha H, et al. Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. Lancet. 1991;338:847–850.
    1. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–1971.
    1. Ngondi J, Gebre T, Shargie EB, Adamu L, Ejigsemahu Y, et al. Evaluation of three years of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma. Trans R Soc Trop Med Hyg 2009

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever